fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

ATOS

Atossa Therapeutics, Inc.

  ( )

Page Views : 616568

vista's key points

  • Atossa is led by Dr. Stephen Quay, MD, PhD. who has invented 7 FDA-approved pharmaceuticals which have helped over 80 million people.
  • Atossa's COVID-19 HOPE Treatment Program uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.
  • Atossa's AT-301 Nasal Spray therapy for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.
  • Atossa is developing their proprietary Topical & Oral Endoxifen to both help prevent as well as to treat breast cancer .
  • Atossa has raised ~$136 million since Dec. 2020 to bolster its balance sheet, extend runway, & increase corporate options since Dec. 2020.
  • Atossa was recently added to the Russell 2000 and Russell 3000 Indexes.
  • On Friday, June 11th, Atossa announced that it has received approval from the Swedish Medical Product Agency (MPA) to initiate a Phase 2 clinical study of its oral Endoxifen for the reduction of mammographic breast density (MBD). Studies conducted by others have shown that MBD reduces the ability of mammograms to detect cancer (sensitivity) and increases the risk of developing breast cancer.
  • On July 7th, Atossa Therapeutics, Inc. (Nasdaq: ATOS), announced that it has received regulatory approval from HREC (Human Research Ethics Committee) to open a clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.

vista's key points

  • Atossa is led by Dr. Stephen Quay, MD, PhD. who has invented 7 FDA-approved pharmaceuticals which have helped over 80 million people.
  • Atossa's COVID-19 HOPE Treatment Program uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.
  • Atossa's AT-301 Nasal Spray therapy for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.
  • Atossa is developing their proprietary Topical & Oral Endoxifen to both help prevent as well as to treat breast cancer .
  • Atossa has raised ~$136 million since Dec. 2020 to bolster its balance sheet, extend runway, & increase corporate options since Dec. 2020.
  • Atossa was recently added to the Russell 2000 and Russell 3000 Indexes.
  • On Friday, June 11th, Atossa announced that it has received approval from the Swedish Medical Product Agency (MPA) to initiate a Phase 2 clinical study of its oral Endoxifen for the reduction of mammographic breast density (MBD). Studies conducted by others have shown that MBD reduces the ability of mammograms to detect cancer (sensitivity) and increases the risk of developing breast cancer.
  • On July 7th, Atossa Therapeutics, Inc. (Nasdaq: ATOS), announced that it has received regulatory approval from HREC (Human Research Ethics Committee) to open a clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.

company profile

 

vista's view

Atossa has added substantial cash resources since Dec. 2020 as they are seeking to use to “accelerate development of our COVID-19 and breast cancer therapies”. Atossa has raised ~$136 million now via registered directs since Dec. 2020 to bolster its balance sheet, extend runway, & increase corporate options. With the additional...

Read More

exclusive content

 

Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates